Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dunad Therapeutics

Request full access

Tunable covalent chemistry for developing oral degradable medicines

Whittlesford, United KingdomFounded 2020Biotech & Life Sciences

About Dunad Therapeutics

Dunad Therapeutics, founded in 2020 by Professor Patrick Gunning and Dr. Diana Kraskouskaya, is a biopharmaceutical company that develops orally bioavailable, small molecule protein degradation therapies. The company operates from Cambridge, UK, and Cambridge, Massachusetts, focusing on creating medicines for oncology and Central Nervous System (CNS) disorders.

The company's core is its proprietary platform that utilizes tunable, mono-valent small molecules to induce the degradation of disease-causing proteins. This technology directly modifies the target protein, a novel mechanism that is designed to overcome challenges faced by other protein degradation technologies, such as achieving oral bioavailability and CNS accessibility. The platform is target-class agnostic, aiming to address proteins that have been considered 'undruggable'.

Co-founder Patrick Gunning, a Professor of Chemistry at the University of Toronto, has an extensive background in medicinal chemistry, focusing on inhibitors for various protein classes. His research group's work was foundational for Dunad. Co-founder Diana Kraskouskaya holds a PhD in Medicinal Chemistry and has experience in co-founding other biotech companies, bringing expertise in company building and drug discovery program strategy.

Dunad's business model involves both advancing its internal pipeline and engaging in strategic collaborations. A significant milestone was a 2021 partnership with Novartis to develop covalent and protein-degrading drugs for up to four targets. The agreement included a $24 million upfront payment and equity investment, with potential milestone payments up to $1.3 billion plus royalties. Under this collaboration, Dunad is responsible for research and discovery up to lead optimization, while Novartis will handle subsequent development and commercialization. The company's initial financing came from Epidarex Capital, and its investor base has expanded to include Alpha Wave Global, BioGeneration Ventures (BGV), and Wellington Partners.

Source: Dealroom company data

At a glance

Founded
2020
Headquarters
Whittlesford, United Kingdom
Sector
Biotech & Life Sciences

Dunad Therapeutics in the Whittlesford ecosystem

Live from Dealroom

The Dunad Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇬🇧 United Kingdom47.1%
🇺🇸 United States29.4%
🇨🇦 Canada5.9%
🇩🇪 Germany5.9%
🇫🇷 France5.9%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dunad Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dunad Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.